<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084678</url>
  </required_header>
  <id_info>
    <org_study_id>ROR-PH-302</org_study_id>
    <nct_id>NCT04084678</nct_id>
  </id_info>
  <brief_title>A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH</brief_title>
  <acronym>CAPACITY</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy&#xD;
      on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from&#xD;
      cardiopulmonary exercise testing (CPET) after 28 weeks of treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ROR-PH-302 is a 28-week multicenter, randomized, double-blind, placebo-controlled study.&#xD;
      Subjects who meet entry criteria will be randomly allocated 2:1 to receive ralinepag or&#xD;
      placebo, in addition to their PAH-specific background therapy, as applicable. The primary&#xD;
      endpoint is change from Baseline in peak VO2 (assessed by CPET) at Week 28. All subjects who&#xD;
      complete the study on study drug through Week 28 will have the option to receive ralinepag in&#xD;
      an open-label extension (OLE) study. Subjects who discontinue study drug prior to Week 28, as&#xD;
      well as those who complete Week 28 on study drug but choose not to participate in the OLE&#xD;
      study, will be contacted every 6 months and at the end of the study to determine their&#xD;
      survival status. Subjects who prematurely discontinue study drug or withdraw from the study&#xD;
      for any reason will not be eligible to enter the OLE study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in peak VO2 assessed by CPET</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Peak VO2 by CPET was measured at Baseline (prior to starting study drug) and Week 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>NT-proBNP was measured at Baseline (prior to starting study drug) and Weeks 4, 8, 12, 16, 20, 24 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Minute Ventilation (VE)/Carbon Dioxide output (VCO2) slope</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>VE/VCO2 slope (from CPET) was calculated at Baseline (prior to starting study drug) and Week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in health-related quality of life measured by the Short Form Health Survey (SF-36) Scores</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>SF-36 was assessed at Baseline (prior to starting study drug) and Weeks 16 and 28. The SF-36 consisted of 36 questions in 8 health categories (Vitality, Physical Functioning, Bodily Pain, General Health Perception, Role Physical, Role Emotional, Social Functioning, and Mental Health). Responses to the questions were graded on a numerical scale, with 1 as the best score and higher numbers as worse scores. The raw scores from the subscales were converted and summed by the Investigator to a total score between 0 and 100 to measure functional health and well-being from the patient's point of view. The final score range was 0 (representing the lowest possible score; worst health state) to 100 (representing the highest possible score; best health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First All-cause Non-elective Hospitalization</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>The time to first all-cause nonelective hospitalization during the study period will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">193</enrollment>
  <condition>PAH</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Hypertension</condition>
  <condition>Connective Tissue Disease</condition>
  <condition>Familial Primary Pulmonary Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Lung Diseases</condition>
  <condition>Respiratory Tract Disease</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Ralinepag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ralinepag</intervention_name>
    <description>Oral ralinepag</description>
    <arm_group_label>Ralinepag</arm_group_label>
    <other_name>APD811</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. Primary diagnosis of PAH .&#xD;
&#xD;
          4. Has had a diagnostic RHC performed at or within 3 years before Screening (or at&#xD;
             Screening if one is not available) that is consistent with the diagnosis of PAH.&#xD;
&#xD;
          5. Has World Health Organization (WHO)/New York Heart Association (NYHA) Functional Class&#xD;
             (FC) II to III symptoms&#xD;
&#xD;
          6. Must be on a stable dose of PAH-specific oral therapy, defined as no change in dose or&#xD;
             regimen for at least 120 days prior to randomization. Allowable PAH-specific therapy&#xD;
             is an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor&#xD;
             (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator. Subjects may be on a stable&#xD;
             dose of either a PDE5-I or a sGC stimulator, not both.&#xD;
&#xD;
          7. Has a 6-minute walk distance (6MWD) of ≥150 meters at Screening.&#xD;
&#xD;
          8. Has a VE/VCO2 slope ≥38 during the Screening CPET, as assessed by the CPET core&#xD;
             laboratory.&#xD;
&#xD;
          9. Has a peak VO2 of ≥10 to &lt;18 mL·kg-1·min-1 during the Screening CPET, as assessed by&#xD;
             the CPET core laboratory.&#xD;
&#xD;
         10. If the subject is taking concomitant medications that may affect the clinical&#xD;
             manifestations of PAH, the subject must be on a stable dose for at least 30 days prior&#xD;
             to randomization. The exception is that the dose of diuretics should remain stable for&#xD;
             at least the 10 days prior to randomization and the dosage maintained throughout the&#xD;
             study.&#xD;
&#xD;
         11. Both male and female subjects agree to use a highly effective method of birth control&#xD;
             throughout the entire study period from informed consent through to the Week 28&#xD;
             Visit/28-day Follow-up Visit, if the possibility of conception exists. Eligible male&#xD;
             and female subjects must also agree not to participate in a conception process during&#xD;
             the study and for 30 days after the final dose of study drug. Eligible male subjects&#xD;
             must agree not to participate in sperm donation for 90 days after the final dose of&#xD;
             study drug.&#xD;
&#xD;
        Women who are surgically sterile or postmenopausal are not considered to be of childbearing&#xD;
        potential. If of childbearing potential, female partners of male study participants should&#xD;
        agree to utilize medically acceptable methods of contraception for the duration of study&#xD;
        participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For subjects with known human immunodeficiency virus-associated PAH, a cluster&#xD;
             designation of differentiation 4 (CD4+) T-cell count &lt;200/mm3 at Screening.&#xD;
&#xD;
          2. Has 3 or more left ventricular disease dysfunction risk factors.&#xD;
&#xD;
          3. Symptomatic coronary disease and/or myocardial infarction within past 6 months.&#xD;
&#xD;
          4. Current symptomatic aortic or mitral valve disease.&#xD;
&#xD;
          5. Has evidence of more than mild lung disease on pulmonary function tests performed&#xD;
             within 1 year prior to, or during, Screening.&#xD;
&#xD;
          6. Has evidence of thromboembolic disease as determined by ventilation-perfusion lung&#xD;
             scan or local standard of care diagnostic evaluation at or after diagnosis of PAH.&#xD;
&#xD;
          7. Current diagnosis of ongoing and clinically significant sleep apnea as defined by the&#xD;
             Investigator.&#xD;
&#xD;
          8. Requires use of supplemental oxygen during CPET.&#xD;
&#xD;
          9. Respiratory exchange ratio &lt;1.0 at Screening CPET as determined by the CPET core&#xD;
             laboratory.&#xD;
&#xD;
         10. Acute non-cardiac disorder that may affect exercise performance or be aggravated by&#xD;
             exercise (eg, infection, renal failure, thyrotoxicosis).&#xD;
&#xD;
         11. Male subjects with a QTcF &gt;450 msec and female subjects with a QTcF &gt;470 msec on&#xD;
             electrocardiogram (ECG) recorded at Screening and analyzed by the central ECG&#xD;
             laboratory. Subjects with evidence of intraventricular conduction delay, defined as a&#xD;
             QRS interval &gt;110 msec, will be excluded if QTcF is &gt;500 msec for both males and&#xD;
             females.&#xD;
&#xD;
         12. Severe chronic liver disease (ie, Child-Pugh Class C), portal hypertension, cirrhosis,&#xD;
             or complications of cirrhosis/portal hypertension (eg, history of variceal hemorrhage,&#xD;
             encephalopathy).&#xD;
&#xD;
         13. Confirmed active infection with hepatitis B virus or hepatitis C virus.&#xD;
&#xD;
         14. Subjects with alanine aminotransferase or aspartate aminotransferase ≥3 times the&#xD;
             upper limit of normal or total bilirubin ≥2 times the upper limit of normal at&#xD;
             Screening.&#xD;
&#xD;
         15. Chronic renal insufficiency as defined by an estimated glomerular filtration rate&#xD;
             using the Modification of Diet in Renal Disease Study equation of &lt;30 mL/min/1.73 m^2&#xD;
             or requiring dialysis at Screening.&#xD;
&#xD;
         16. Hemoglobin concentration &lt;9 g/dL at Screening.&#xD;
&#xD;
         17. Subjects treated with an intravenous or subcutaneous prostacyclin pathway agent (eg,&#xD;
             epoprostenol, treprostinil, or iloprost) for PAH at any time (use in vasoreactive&#xD;
             testing is permitted).&#xD;
&#xD;
         18. Subjects currently on or who have been treated with an inhaled or oral prostacyclin&#xD;
             pathway agent (iloprost, treprostinil, beraprost, or selexipag) within 120 days prior&#xD;
             to randomization.&#xD;
&#xD;
         19. Subject has pulmonary veno-occlusive disease.&#xD;
&#xD;
         20. Malignancy diagnosed and/or treated within 3 years of Screening, with the exception of&#xD;
             localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ&#xD;
             carcinoma of the cervix excised with curative intent.&#xD;
&#xD;
         21. Subject tests positive for amphetamine, cocaine, methamphetamine,&#xD;
             methylenedioxymethamphetamine, or phencyclidine in urine drug screen performed at&#xD;
             Screening, or has a recent history (6 months) of alcohol or drug abuse. Subjects will&#xD;
             not be excluded due to a positive drug screen caused by prescribed medications.&#xD;
&#xD;
         22. Initiation or discontinuation of a cardio-pulmonary rehabilitation program based upon&#xD;
             exercise within 90 days prior to Screening and/or planned during study participation.&#xD;
&#xD;
         23. Prior participation in any study of ralinepag or another interventional clinical study&#xD;
             with medicinal products within 30 days prior to Screening. Concurrent participation in&#xD;
             registry or observational studies is allowed, if the subject can fulfill all other&#xD;
             entry criteria and comply with all study procedures.&#xD;
&#xD;
         24. Any reason that, in the opinion of the Investigator, precludes the subject from&#xD;
             participating in the study (eg, any previous or intercurrent medical condition) that&#xD;
             may increase the risk associated with study participation or that would confound study&#xD;
             analysis (eg, right-to-left shunt detected during CPET) or impair study participation&#xD;
             or cooperation.&#xD;
&#xD;
         25. Known hypersensitivity to ralinepag or any of the excipients.&#xD;
&#xD;
         26. Life expectancy &lt;12 months based on the Investigator's opinion.&#xD;
&#xD;
         27. Women who are pregnant, lactating, or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>United Therapeutics Global Medical Information</last_name>
    <phone>919-485-8350</phone>
    <email>clinicaltrials@unither.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center (University of Arizona)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austin Derma</last_name>
      <phone>520-626-3285</phone>
      <email>derma1@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Franz Rischard, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center (La Jolla)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Martinez Ceren</last_name>
      <phone>858-657-7135</phone>
      <email>PMM001@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Fernandes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Nicotera</last_name>
      <phone>720-848-7719</phone>
      <email>Lisa.Nicotera@CUAnschutz.edu</email>
    </contact>
    <investigator>
      <last_name>David Badesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Underwood</last_name>
      <phone>303-398-1518</phone>
      <email>UnderwoodJ@NJHealth.org</email>
    </contact>
    <investigator>
      <last_name>Marjorie George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital/University of South Florida Center for Advanced Lung Disease and Lung Transplant</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Grube</last_name>
      <phone>813-844-8624</phone>
      <email>klgrube@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo Restrepo-Jaramillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Capobianco</last_name>
      <phone>617-636-6304</phone>
      <email>ccapobianco@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Ioana Preston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Kleis</last_name>
      <phone>614-366-7843</phone>
      <email>melissa.kleis@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Veronica Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Ciudad Autónoma de Bs. As.</city>
        <zip>1280</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Varela Elizabeth</last_name>
      <phone>+54 1523091096</phone>
      <email>evarela@hbritanico.com.ar</email>
    </contact>
    <investigator>
      <last_name>Felipe Chertcoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiología de Corrientes</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Salazan</last_name>
      <phone>+54739 5009978</phone>
      <email>mariajosegalarza@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Perna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>North Ryde</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepal Wakade</last_name>
      <phone>+612 98122974</phone>
      <email>deepal.wakade@mq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Martin Brown, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital, Dept Respiratory and Sleep Medicine</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Burns</last_name>
      <phone>+61288907785</phone>
      <email>Tracey.burns@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>John Wheatley, FRACP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pietsch</last_name>
      <phone>+ 61 7 3139 7254</phone>
      <email>Maria.pietsch@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>John Feenstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystal Rudland</last_name>
      <phone>+61 7 3176 5394</phone>
      <email>Krystal.rudland@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Gregory J Keir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH, Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Steinkellner</last_name>
      <phone>+ 43 732 7676 4415</phone>
      <email>Claudia.steinkellner@ordensklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Regina Steringer-Mascherbauer, Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKH Wien, Innere Med. II, Kardiologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kohlbacher</last_name>
      <phone>+43 1 40400 62160</phone>
      <email>lisa.kohlbacher@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Irene Lang, Univ. Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasme University Hospital - Department of Cardiology</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Clippel</last_name>
      <phone>+32 2 555 5845</phone>
      <email>Marie.de.clippel@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc Vachiéry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gasthuisberg University Hospital - Department of Pulmonology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Hermans</last_name>
      <phone>+32 1634 6842</phone>
      <email>Isabelle.hermans@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Marion Delcroix, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madre Teresa</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30441-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Mancuzo</last_name>
      <phone>+553133398389</phone>
      <email>pesquisa.clinica@hospitalmadreteresa.org.br</email>
    </contact>
    <investigator>
      <last_name>Frederico Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thaís de Oliveira Rodrigues Sanzovo</last_name>
      <phone>+55 (11) 55792581</phone>
      <email>Oliveira.rodrigues@huhsp.org.br</email>
    </contact>
    <investigator>
      <last_name>Jaquelina Arakaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - InCor-HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Cassimiro Nóbrega</last_name>
      <phone>+ 55 11 2661-5109</phone>
      <email>luciana.cassimiro@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>Rogério de Souza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Hipertensão Pulmonar</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035074</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natália Berwig</last_name>
      <phone>+55 (51) 3213-7068</phone>
      <email>nataliaalice@haprs.com.br</email>
    </contact>
    <investigator>
      <last_name>Gisela Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Gosbee</last_name>
      <phone>+1 403 943 4759</phone>
      <email>Jean.gosbee@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Mitesh Thakrar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Webster</last_name>
      <phone>+1 780-407-6943</phone>
      <email>lwebster@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Evangelos Michelakis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre- Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila MacBean</last_name>
      <phone>+1 5196858500 ext. 76094</phone>
      <email>Leila.macbean@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Sanjay Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik-Heidelberg, Zentrum für Pulmonale Hypertonie</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Maria Heier</last_name>
      <phone>+496221 396 8234</phone>
      <email>Eva-maria.heier@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ekkehard Grünig, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Vanelli</last_name>
      <phone>+39 (02) 55033538</phone>
      <email>dyspnea.lab.policlinico.mi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marco Vicenzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Mattavelli</last_name>
      <phone>+390258002787</phone>
      <email>irene.mattavelli@cardiologicomonzino.it</email>
    </contact>
    <investigator>
      <last_name>Piergiuseppe Agostoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca D'Alessandro</last_name>
      <phone>+34 90633162</phone>
      <email>dalessandro.francesca@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Badagliacca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Ptaszyńska-Kopczyńska</last_name>
      <phone>+48858318656</phone>
      <email>kasia.ptaszynska@op.pl</email>
    </contact>
    <investigator>
      <last_name>Karol Kaminski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Oddział Kardiologiczny</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Bąbik</last_name>
      <phone>+48 22 710 30 52</phone>
      <email>paulina.babik@ecz-otwock.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Torbicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia López</last_name>
      <phone>+34 932746107</phone>
      <email>solopez@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Manuel López Meseguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Sanz</last_name>
      <phone>+34 932275779</phone>
      <email>mdsanz@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Isabel Vich, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Parra</last_name>
      <phone>+34 917792642</phone>
      <email>nuriaochoaparra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Subias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostacyclin</keyword>
  <keyword>Connective Tissue Disease-Associated</keyword>
  <keyword>Cardiopulmonary Exercise Capacity (CPET)</keyword>
  <keyword>IP Receptor Agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

